Clareon® Vivity®
Extended Vision IOL

Alcon

PRESBYOPIA CORRECTION WITH A CONSISTENT MONOFOCAL VISUAL DISTURBANCE PROFILE[1-3,11^]

Predictable results you can trust to meet patient expectations, backed by over 1 million implants worldwide[1-5,11‡^]

Clareon® Vivity® provides a monofocal visual disturbance profile[3§]

Proportion of subjects who responded NOT AT ALL to the Question

In the Past 7 Days, How Much Were You Bothered With?[3†]



TECNIS* PureSee* demonstrated an **asymmetric halo image** when decentered[6].

Based on bench data

In a retrospective study,

More than 50% of TECNIS* PureSee* patients reported experiencing glare or halo occasionally, or more often[7#]

1-Month patient reported frequency (n=103):



^Clinical studies were performed on the AcrySof IQ Vivity IOL; AcrySof IQ Vivity and Clareon Vivity are optically equivalent. ‡Based on worldwide sales of AcrySof IQ Vivity® and Clareon® Vivity® IOLs. † From QUVID, Questionnaire for Visual Disturbances, answers collected at visit 1. The answers that could be chosen by the subjects: Not at all, A little bit, Somewhat, Quite a bit and Very much. § Data obtained from a prospective/retrospective, multicenter, non-randomized, parallel-group, controlled, assessor-masked interventional study. Vivity® group: Clareon® Vivity®/Vivity® Toric Extended Vision IOLs (CNWET0, CNWET3-T6, CCWET0, CCWET3-T6) (Vivity®, Vivity® Toric, Vivity® Non-Toric) Monofocal group: Clareon®/Clareon® Toric Aspheric IOL(s) (SY60WF, CNW0T3-T6, CC60WF, CCW0T3-T6) and Clareon® with AutonoMe® (CCA0T0, CNA0T0) (Monofocal, Monofocal Toric). *Trademarks are the property of their respective owners. #Short-Term Clinical Outcomes of a New Purely Refractive Extended Depth of Focus Intraocular Lens; n= 103 patients

TECNIS* PureSee* has ~42% lower image contrast (MTF) at 66 cm compared to Clareon® Vivity®[8**]

USAF-resolution targets recorded at a defocus range of -1.5D with a 3 mm aperture[8]**



In a recent retrospective, case-controlled study, **Vivity® provided superior BCVA than TECNIS* PureSee* at 66cm[9†]**



In a recent retrospective cohort study, **Data showed Vivity® had a broader defocus curve than TECNIS* PureSee* at 0.2 logMAR[10‡]**



*Trademarks are the property of their respective owners. **Polychromatic through focus MTF at 50 lp/mm with 3 mm aperture at -1.5D with 3 mm aperture.
° Snellen VA was converted from logMARVA. A Snellen notation of 20/20-2 or better indicates a logMARVA of 0.04 or better, which means 3 or more of the 5 Early Treatment Diabetic Retinopathy Study chart letters in the line were identified correctly.† Monocular BCVA for Vivity (n=19 pairs of eyes) vs PureSee* (n=16 pairs of eyes) at 66 cm 1-month post-op: p-value=0.0005. ‡ N=34 (17 patients in each binocular cohort displayed); asterisks represent pairwise comparisons at each defocus.

1. Bala C, et al Multi-country clinical outcomes of a new nondiffractive presbyopia-correcting intraocular lens. J Cataract Refract Surg. 2022;48(2):136–143. **2.** McCabe C, et al Clinical outcomes in a U.S. registration study of a new EDOF intraocular lens with a non-diffractive design. J Cataract Refract Surg. 2022;48(11):1297–1304. **3.** Berdahl P, et al. Visual Performance of a Novel Wavefront Shaping EDOF IOL. J Cataract Refract Surg doi:10.1097/j.jcrs.0000000000001742. **4.** Howes F, et al. Vivity registry outcomes. J Refract Surg. 2025;41(2):e131.doi:10.3928/1081597X-20241230-01. **5.** Alcon data on file, 2024 [REF-24102] **6.** Alcon data on file, 2024 [REF-27934]. **7.** Chung et al. Short-Term Clinical Outcomes of a New Purely Refractive Extended Depth of Focus Intraocular Lens; n= 103 patients. **8.** Niknahad A, et al. Evaluation of Clareon Vivity and PureSee intraocular lenses: optical quality, depth of focus and misalignment effects. Sci Rep. 2025;15(1):26943. Published 2025 Jul 24.. **9.** N. Tuli and P. J. Harasymowycz, "A comparative analysis of extended-depth-of-focus and enhanced monofocal intraocular lenses in open-angle glaucoma," poster presented at the ASCRS 2025 Annual Meeting, Los Angeles, CA, USA, Apr. 25–28, 2025. **10.** J. Jeong et al., Clinical comparison of Newly Launched Two Extended Depth of Field IOLs, Free paper presented at the APACRS Annual Meeting, Ahmedabad, India, Aug. 21-23, 2025. **11.** Alcon data on file, 2022, REF-15172.

Alcon medical device(s) comply with the current legislation for medical devices. Please refer to relevant product's instructions for use for a complete list of indications, contraindications, warnings and serious incidents.